168 related articles for article (PubMed ID: 15205208)
1. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
Thödtmann R; Depenbrock H; Dumez H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
J Clin Oncol; 1999 Oct; 17(10):3009-16. PubMed ID: 10506594
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
Takimoto CH; Hammond-Thelin LA; Latz JE; Forero L; Beeram M; Forouzesh B; de Bono J; Tolcher AW; Patnaik A; Monroe P; Wood L; Schneck KB; Clark R; Rowinsky EK
Clin Cancer Res; 2007 May; 13(9):2675-83. PubMed ID: 17473199
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.
Stover DG; Lockhart AC; Berlin JD; Chan E; Sandler AB; Sosman JA; Middlebrook V; Nicol S; Rothenberg ML
Invest New Drugs; 2008 Aug; 26(4):339-45. PubMed ID: 18463792
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
Hensley ML; Larkin J; Fury M; Gerst S; Tai DF; Sabbatini P; Konner J; Orlando M; Goss TL; Aghajanian CA
Clin Cancer Res; 2008 Oct; 14(19):6310-6. PubMed ID: 18829514
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.
Alberts SR; Kim GP; Mahoney MR; Gornet MK; Rubin J; Ames M; Goetz MP; Weinshilboum RM; Nicol SJ; Goldberg RM
Clin Colorectal Cancer; 2007 Jul; 6(8):572-7. PubMed ID: 17681103
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Rowinsky EK; Beeram M; Hammond LA; Schwartz G; De Bono J; Forouzesh B; Chu Q; Latz JE; Hong S; John W; Nguyen B
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):532-9. PubMed ID: 17255275
[TBL] [Abstract][Full Text] [Related]
14. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
15. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
[TBL] [Abstract][Full Text] [Related]
16. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies.
Burris HA; Infante JR; Jewell RC; Spigel DR; Greco FA; Thompson DS; Jones SF
Oncologist; 2010; 15(9):954-60. PubMed ID: 20798192
[TBL] [Abstract][Full Text] [Related]
18. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
Dy GK; Suri A; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Atherton PJ; Hanson LJ; Burch PA; Rubin J; Erlichman C; Adjei AA
Cancer Chemother Pharmacol; 2005 Jun; 55(6):522-30. PubMed ID: 15754203
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.
Nakagawa K; Kudoh S; Matsui K; Negoro S; Yamamoto N; Latz JE; Adachi S; Fukuoka M
Br J Cancer; 2006 Sep; 95(6):677-82. PubMed ID: 16940981
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.
Adjei AA; Erlichman C; Sloan JA; Reid JM; Pitot HC; Goldberg RM; Peethambaram P; Atherton P; Hanson LJ; Alberts SR; Jett J
J Clin Oncol; 2000 Apr; 18(8):1748-57. PubMed ID: 10764436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
